Skip to main content

Himbacine

ADVERTISEMENT
Identification
Molecular formula
C23H35N2O
CAS number
749-83-3
IUPAC name
(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol
State
State

At room temperature, himbacine is a solid. It remains stable under normal temperature and pressure conditions, maintaining its solid state unless subject to higher thermal energy which may lead to melting or boiling.

Melting point (Celsius)
218.00
Melting point (Kelvin)
491.15
Boiling point (Celsius)
579.15
Boiling point (Kelvin)
852.30
General information
Molecular weight
341.54g/mol
Molar mass
341.5120g/mol
Density
1.1200g/cm3
Appearence

Himbacine is typically observed as a white to off-white crystalline solid. It may also be found in a powder form. The compound is not known for having a distinctive color.

Comment on solubility

Solubility of (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol

The solubility of complex organic compounds like (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol can be quite intriguing due to their unique structural characteristics.

Generally, the solubility of such compounds can be influenced by several factors:

  • Polarity: The extent to which the compound possesses polar functional groups plays a significant role in its solubility in polar solvents, such as water, whereas non-polar solvents suit non-polar compounds.
  • Hydrogen Bonding: The ability of the compound to form hydrogen bonds can enhance solubility in protic solvents.
  • Molecular Size : Larger, more complex molecular structures may present solubility challenges due to limited mobility in solvents.
  • Temperature: Increased temperature often aids in dissolving solids by providing the energy necessary to overcome intermolecular forces.

With this specific compound, due to its intricate structure and multiple fused rings, its solubility in common solvents may be limited. However, it could exhibit varying solubility characteristics in organic solvents like ethanol and chloroform depending on its specific interactions with solvent molecules.

In conclusion, the solubility behavior of (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol is a combination of its unique structural properties and the environmental conditions, making its study essential for applications in various fields.

Interesting facts

Interesting Facts about (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol

This compound, known for its complex structural conformation, belongs to the category of bicyclic and polycyclic compounds, which are often an area of keen interest within organic chemistry. The intricate arrangement of atoms and the presence of multiple interconnected rings provide a unique challenge for synthetic chemists.

Key Features

  • Stereochemistry: The specific stereochemical configuration indicated by its nomenclature plays a crucial role in the compound's chemical behavior and reactivity. The designated stereocenters highlight its chiral nature, which can lead to different functional properties.
  • Diaza Structure: The presence of nitrogen atoms in the rings (notably 6,7-diazapentacyclo) significantly impacts the compound's chemical properties, such as its reactivity and binding affinity in biological systems.
  • Potential Applications: With its complex structure, this compound may exhibit useful biological activities, potentially serving as a lead compound for drug development or as a model for studying interactions in medicinal chemistry.

Such compounds often pique the interest of researchers due to their possibility of engaging in intricate reactions, including ring-opening and functionalization, which can lead to the synthesis of novel derivatives. As notable quotes in the field suggest, “The intricacy of chemical structure is a beautiful complexity waiting to be explored.”

Overall, the study of compounds like (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol not only advances our understanding of chemical principles but also expands the horizon for innovative applications in pharmaceuticals and materials science.

Synonyms
stanozolol
Winstrol
Androstanazole
10418-03-8
Androstanazol
Stanazolol
Tevabolin
Winstrol Depot
Strombaject
Estazol
Estanozolol
Winstroid
Winstrol V
Stanozololum
WIN 14833
Stanozolo
Stanozolol ciii
Stanozolol (1'H form)
HSDB 3185
Stanozolol (2'H form)
Stanozololum [INN-Latin]
Estanozolol [INN-Spanish]
EINECS 233-894-8
UNII-4R1VB9P8V3
NSC 43193
NSC-43193
WIN-14833
NSC 233046
4R1VB9P8V3
CHEBI:9249
DTXSID3044128
17-Methyl-2'H-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol
NSC-233046
2'H-Androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-
17-Methyl-5alpha-androstano(3,2-c)pyrazol-17beta-ol
17-beta-Hydroxy-17-alpha-methylandrostano(3,2-c)pyrazole
17beta-Hydroxy-17alpha-methyl-androstano(3,2-c)pyrazole
17-Methylpyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol
17beta-Hydroxy-17-methyl-5alpha-androstano(3,2-c)pyrazole
DTXCID1024128
17-Methyl-pyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol
17alpha-Methyl-17beta-hydroxy-5alpha-androstano(3,2-c)pyrazole
2'H-5alpha-Androst-2-eno(3,2-c)pyrazol-17beta-ol, 17-methyl-
2,3-(4',3'-Pyrazolo)-5alpha-androstan-17beta-ol, 17-methyl-
NSC43193
WIN14833
1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-Hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol
Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-
Stanozolol [USAN:USP:INN:BAN:JAN]
Methylstanazol
1'H-Androstano(3,2-c)pyrazol-17-ol, 17-methyl-, (5-alpha,17-beta)-
Stanozololum (INN-Latin)
Estanozolol (INN-Spanish)
STANOZOLOL (MART.)
STANOZOLOL [MART.]
Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-
STANOZOLOL (EP MONOGRAPH)
STANOZOLOL [EP MONOGRAPH]
STANOZOLOL CIII (USP-RS)
STANOZOLOL CIII [USP-RS]
STANOZOLOL (USP MONOGRAPH)
STANOZOLOL [USP MONOGRAPH]
Stanozolol (USAN:USP:INN:BAN:JAN)
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
stanozololo
Stanazol
NSC233046
Winstrol-V Tablets
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta(5,6)naphtho(1,2-f)indazol-1-ol
Winstrol-V Chewable Tablets
Winstrol-V Sterile Suspension
A14AA02
17-METHYL-2H-5ALPHA-ANDROST-2-ENO
17BETA-HYDROXY-17ALPHA-METHYL-ANDROSTANO
17beta-HYDROXY-17alpha-METHYL-5alpha-ANDROSTANO(3,2-C)PYRAZOLE
1'H-ANDROSTANO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5alpha,17beta)-
2'H-ANDROST-2-ENO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5alpha,17beta)
1,2,3,3A,3B,4,5,5A,6,8,10,10A,10B,11,12,12A-HEXADECAHY DRO-1,10A,12A-TRIMETHYLCYCLOPENTA
233-894-8
10418-03-8 302-96-5
Stromba
Anabol
Androstanazolestanazol
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
Stanozolo [DCIT]
Androstanazole (VAN)
Winstrol-V
(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol
SR-05000001522
302-96-5
17.BETA.-HYDROXY-17.ALPHA.-METHYL-5.ALPHA.-ANDROSTANO(3,2-C)PYRAZOLE
Winstrol (TN)
STANOZOLOL [MI]
STANOZOLOL [INN]
STANOZOLOL [JAN]
STANOZOLOL [HSDB]
STANOZOLOL [USAN]
STANOZOLOL [VANDF]
STANOZOLOL [WHO-DD]
SCHEMBL44099
SCHEMBL44101
Stanozolol (JAN/USP/INN)
MLS001424321
17-Methyl-2'H-5.alpha.-androst-2-eno(3,2-c)pyrazol-17.beta.-ol
Stanozolol, analytical standard
STANOZOLOL [GREEN BOOK]
CHEMBL2079587
STANOZOLOL [ORANGE BOOK]
GTPL10369
LKAJKIOFIWVMDJ-IYRCEVNGSA-N
GLXC-10566
HMS2052H11
HMS2090P03
HMS3713K06
BCP12548
HY-B0899
Stanozolol, 1mg/ml in Acetonitrile
Tox21_113993
MSK8501-100A
AKOS005067278
Stanozolol 1.0 mg/ml in Acetonitrile
CCG-101186
CCG-220452
CS-4363
DB06718
NC00436
NCGC00344550-01
AC-16140
AC-33164
AS-35198
CPD000058878
FS156771
SMR000058878
CAS-10418-03-8
NS00008736
C07311
D00444
Stanozolol Solution in Acetonitrile, 100ug/mL
17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol
AB00443942-03
AB00443942-05
SR-05000001522-1
SR-05000001522-2
17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole
17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole
17b-Hydroxy-17a-methyl-5a-androstano[3,2-c]pyrazole
BRD-K46791647-001-01-2
Q63409446
17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol
Stanozolol, European Pharmacopoeia (EP) Reference Standard
(5a,17b)-17-methyl-2'H-Androst-2-eno[3,2-c]pyrazol-17-ol
2,3'-Pyrazolo)-5.alpha.-androstan-17.beta.-ol, 17-methyl-
17-METHYL-5.ALPHA.-ANDROSTANO(3,2-C)PYRAZOL-17.BETA.-OL
2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8CI)
17alpha-Methyl-17beta-hydroxy-5alpha-androst-2-eno(3,2-c)-pyrazole
1'H-ANDROSTANO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5.ALPHA.,17.BETA.)-
2'H-ANDROST-2-ENO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5.ALPHA.,17.BETA.)
Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-17-ol deriv.
(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5-dien-17-ol
1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-Cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol
Cyclopenta[7,3-c]pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-